Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. 23. April 2019 1. Januar 2015 Share EmailTwitterFacebookGoogle +PinterestTumblrLinkedinVkontakte